CO6390114A2 - Anticuerpos anti cxcr4 para el tratamiento - Google Patents
Anticuerpos anti cxcr4 para el tratamientoInfo
- Publication number
- CO6390114A2 CO6390114A2 CO11162444A CO11162444A CO6390114A2 CO 6390114 A2 CO6390114 A2 CO 6390114A2 CO 11162444 A CO11162444 A CO 11162444A CO 11162444 A CO11162444 A CO 11162444A CO 6390114 A2 CO6390114 A2 CO 6390114A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- treatment
- cxcr4
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con anticuerpos aislados novedosos, o los compuestos derivados a los fragmentos funcionales de los mismos, capaces de unirse a CXCR4 pero también para inducir el cambio conformacional de los homodímeros CXCR4 y capaces de inhibir la replicación aislada principal del VIH-1 en PBMC. Más particularmente, la presente invención se relaciona con los anticuerpos monoclonales 515H7 y 301aE5, específicos para la proteína CXCR4, así como también su uso para el tratamiento de infección por VIH. También se cubren composiciones farmacéuticas compuestas de tales anticuerpos y un proceso para la selección de tales anticuerpos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17368009P | 2009-04-29 | 2009-04-29 | |
EP09159076A EP2246364A1 (en) | 2009-04-29 | 2009-04-29 | Anti CXCR4 antibodies for the treatment of HIV |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6390114A2 true CO6390114A2 (es) | 2012-02-29 |
Family
ID=41060014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11162444A CO6390114A2 (es) | 2009-04-29 | 2011-11-25 | Anticuerpos anti cxcr4 para el tratamiento |
Country Status (26)
Country | Link |
---|---|
US (3) | US9090686B2 (es) |
EP (2) | EP2246364A1 (es) |
JP (1) | JP5800802B2 (es) |
KR (1) | KR20120039525A (es) |
CN (1) | CN102459343B (es) |
AU (1) | AU2010243526B2 (es) |
BR (2) | BRPI1011540A2 (es) |
CA (1) | CA2759989A1 (es) |
CL (1) | CL2011002664A1 (es) |
CO (1) | CO6390114A2 (es) |
ES (1) | ES2534313T3 (es) |
GE (1) | GEP20146181B (es) |
HK (1) | HK1165813A1 (es) |
HU (1) | HUE025083T2 (es) |
IL (1) | IL215919A0 (es) |
MA (1) | MA33285B1 (es) |
MX (1) | MX2011011285A (es) |
MY (1) | MY155400A (es) |
NZ (1) | NZ596712A (es) |
PL (1) | PL2424897T3 (es) |
RU (1) | RU2573902C2 (es) |
SG (1) | SG175353A1 (es) |
TN (1) | TN2011000534A1 (es) |
UA (1) | UA107929C2 (es) |
WO (1) | WO2010125162A1 (es) |
ZA (1) | ZA201108330B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
JP2014504147A (ja) * | 2010-10-27 | 2014-02-20 | ピエール、ファーブル、メディカマン | Hivの治療用抗体 |
CA2981662C (en) | 2011-01-14 | 2019-02-05 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
CN106102837B (zh) | 2013-12-02 | 2020-10-13 | 艾伦戴蒙德艾滋病研究中心 | 双特异性hiv-1-中和抗体 |
PL3390441T3 (pl) | 2015-12-15 | 2022-01-10 | Gilead Sciences, Inc. | Przeciwciała neutralizujące ludzki wirus niedoboru odporności |
CA3026477A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv gp120およびcd3を標的とする多重特異性抗体 |
US11180575B2 (en) | 2018-12-28 | 2021-11-23 | Corn Products Development, Inc. | Thermally inhibited starch and process for making |
EP3774840A1 (en) | 2018-03-27 | 2021-02-17 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
CN111214650A (zh) * | 2018-11-23 | 2020-06-02 | 广州溯原生物科技有限公司 | 一种hiv抗原-受体三聚体复合物的解离因子的应用 |
US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
US20220220430A1 (en) | 2019-05-23 | 2022-07-14 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
JP2023511331A (ja) * | 2020-01-16 | 2023-03-17 | カイロス セラピューティクス, インコーポレイテッド | 骨髄腫細胞および卵巣がん細胞に特異的なヒト化抗体 |
JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル-マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
US12006353B2 (en) * | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
ES2101834T3 (es) * | 1990-11-27 | 1997-07-16 | Biogen Inc | Anticuerpos anti-cd4 que bloquean sincitios inducidos por vih. |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994007921A1 (en) * | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
AU1834197A (en) * | 1996-01-30 | 1997-08-22 | National Institutes Of Health, The | Cells expressing both human cd4 and cxcr4 |
US20030049251A1 (en) * | 1999-12-08 | 2003-03-13 | Barbas Carlos F. | Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1 |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
RU2006102570A (ru) * | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Антитела и их применение |
US20080039428A1 (en) * | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
WO2008037419A1 (en) * | 2006-09-29 | 2008-04-03 | F. Hoffmann-La Roche Ag | Antibodies against ccr5 and uses thereof |
JP5374360B2 (ja) * | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | 抗grp78抗体を有効成分として含む医薬組成物 |
KR20100133012A (ko) * | 2008-05-14 | 2010-12-20 | 일라이 릴리 앤드 캄파니 | 항-cxcr4 항체 |
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
KR101965585B1 (ko) * | 2009-10-29 | 2019-04-04 | 얀센 바이오테크 인코포레이티드 | 항체 글리코실화 변이체 |
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
-
2009
- 2009-04-29 EP EP09159076A patent/EP2246364A1/en not_active Withdrawn
-
2010
- 2010-04-29 GE GEAP201012429A patent/GEP20146181B/en unknown
- 2010-04-29 RU RU2011148077/10A patent/RU2573902C2/ru not_active IP Right Cessation
- 2010-04-29 CN CN201080028221.XA patent/CN102459343B/zh not_active Expired - Fee Related
- 2010-04-29 UA UAA201114024A patent/UA107929C2/ru unknown
- 2010-04-29 JP JP2012507772A patent/JP5800802B2/ja not_active Expired - Fee Related
- 2010-04-29 MA MA34368A patent/MA33285B1/fr unknown
- 2010-04-29 SG SG2011078334A patent/SG175353A1/en unknown
- 2010-04-29 AU AU2010243526A patent/AU2010243526B2/en not_active Ceased
- 2010-04-29 WO PCT/EP2010/055863 patent/WO2010125162A1/en active Application Filing
- 2010-04-29 EP EP10721376.1A patent/EP2424897B1/en active Active
- 2010-04-29 BR BRPI1011540-4A patent/BRPI1011540A2/pt not_active IP Right Cessation
- 2010-04-29 MY MYPI2011005123A patent/MY155400A/en unknown
- 2010-04-29 ES ES10721376.1T patent/ES2534313T3/es active Active
- 2010-04-29 KR KR1020117027755A patent/KR20120039525A/ko not_active Application Discontinuation
- 2010-04-29 HU HUE10721376A patent/HUE025083T2/en unknown
- 2010-04-29 CA CA2759989A patent/CA2759989A1/en not_active Abandoned
- 2010-04-29 MX MX2011011285A patent/MX2011011285A/es active IP Right Grant
- 2010-04-29 NZ NZ596712A patent/NZ596712A/xx not_active IP Right Cessation
- 2010-04-29 PL PL10721376T patent/PL2424897T3/pl unknown
- 2010-10-27 US US12/913,300 patent/US9090686B2/en not_active Expired - Fee Related
-
2011
- 2011-10-21 TN TNP2011000534A patent/TN2011000534A1/en unknown
- 2011-10-25 IL IL215919A patent/IL215919A0/en unknown
- 2011-10-26 CL CL2011002664A patent/CL2011002664A1/es unknown
- 2011-10-27 BR BR112013009984A patent/BR112013009984A2/pt not_active IP Right Cessation
- 2011-10-27 US US13/823,182 patent/US20130174288A1/en not_active Abandoned
- 2011-11-14 ZA ZA2011/08330A patent/ZA201108330B/en unknown
- 2011-11-25 CO CO11162444A patent/CO6390114A2/es active IP Right Grant
-
2012
- 2012-07-04 HK HK12106487.3A patent/HK1165813A1/xx not_active IP Right Cessation
-
2015
- 2015-06-22 US US14/745,866 patent/US20160031995A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6390114A2 (es) | Anticuerpos anti cxcr4 para el tratamiento | |
CO6571881A2 (es) | Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer | |
GT201200258A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
CR20110509A (es) | Composicion farmaceutica | |
DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
EA200970581A1 (ru) | Кристаллическое твёрдое основание разагилина | |
ECSP14013325A (es) | Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr) | |
UY34116A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
GT200900231A (es) | Moduladores 2-aminopirimidina del receptor de histamina h4 | |
CL2009000860A1 (es) | Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer. | |
CR20130016A (es) | ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
UY32728A (es) | Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia | |
BRPI0909040B8 (pt) | derivados de azetidina e ciclobutano, seus usos, e composição | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
GT201100023A (es) | Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos | |
CL2012002782A1 (es) | Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros. | |
BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
PA8784001A1 (es) | Oxazolidinonas sustituidas y su uso | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
CR11196A (es) | Compuestos quimicos | |
CO6541545A2 (es) | Compuestos de espiropiperidina como antagonistas del receptor orl-1 | |
UY32574A (es) | Antagonistas del receptor cxcr3 | |
CR10609A (es) | Moduladores de benzofuro-y benzotienopirimidina del receptor h4 de histamina | |
DOP2012000250A (es) | COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |